結腸がん:治療薬開発パイプライン分析

◆英語タイトル:Colon Cancer - Pipeline Review, H2 2017
◆商品コード:GMDHC10019IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2017年12月13日
◆ページ数:773
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD5,000 ⇒換算¥550,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD7,500 ⇒換算¥825,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

当調査レポートでは、世界における結腸がんの治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。
・イントロダクション
・結腸がんの概要
・結腸がん治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・結腸がんパイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・企業別、開発中の製品
・大学/研究機関別、研究中の製品
・結腸がん治療薬開発に取り組んでいる企業:企業別製品パイプライン
・結腸がん治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Colon Cancer – Pipeline Review, H2 2017

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Colon Cancer – Pipeline Review, H2 2017, provides an overview of the Colon Cancer (Oncology) pipeline landscape.

Colon cancer is cancer that starts in the large intestine (colon). There is no single cause of colon cancer. Nearly all colon cancers begin as noncancerous (benign) polyps, which slowly develop into cancer. Many cases of colon cancer have no symptoms. The following symptoms may indicate colon cancer abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, or other change in bowel habits, narrow stools and weight loss with no known reason. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Colon Cancer – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Colon Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Colon Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Colon Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 12, 41, 5, 163, 21 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 3, 46 and 17 molecules, respectively.

Colon Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Colon Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Colon Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Colon Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Colon Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Colon Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Colon Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Colon Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Table of Contents 2
Introduction 7
Colon Cancer – Overview 8
Colon Cancer – Therapeutics Development 9
Colon Cancer – Therapeutics Assessment 43
Colon Cancer – Companies Involved in Therapeutics Development 67
Colon Cancer – Drug Profiles 126
Colon Cancer – Dormant Projects 718
Colon Cancer – Discontinued Products 730
Colon Cancer – Product Development Milestones 731
Appendix 741

List of Tables
Number of Products under Development for Colon Cancer, H2 2017 40
Number of Products under Development by Companies, H2 2017 42
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 43
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 44
Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017 45
Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017 46
Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017 47
Number of Products under Development by Companies, H2 2017 (Contd..6), H2 2017 48
Number of Products under Development by Companies, H2 2017 (Contd..7), H2 2017 49
Number of Products under Development by Companies, H2 2017 (Contd..8), H2 2017 50
Number of Products under Development by Companies, H2 2017 (Contd..9), H2 2017 51
Number of Products under Development by Companies, H2 2017 (Contd..10), H2 2017 52
Number of Products under Development by Universities/Institutes, H2 2017 53
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 55
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017 56
Products under Development by Companies, H2 2017 57
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 58
Products under Development by Companies, H2 2017 (Contd..2), H2 2017 59
Products under Development by Companies, H2 2017 (Contd..3), H2 2017 60
Products under Development by Companies, H2 2017 (Contd..4), H2 2017 61
Products under Development by Companies, H2 2017 (Contd..5), H2 2017 62
Products under Development by Companies, H2 2017 (Contd..6), H2 2017 63
Products under Development by Companies, H2 2017 (Contd..7), H2 2017 64
Products under Development by Companies, H2 2017 (Contd..8), H2 2017 65
Products under Development by Companies, H2 2017 (Contd..9), H2 2017 66
Products under Development by Companies, H2 2017 (Contd..10), H2 2017 67
Products under Development by Companies, H2 2017 (Contd..11), H2 2017 68
Products under Development by Companies, H2 2017 (Contd..12), H2 2017 69
Products under Development by Universities/Institutes, H2 2017 70
Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 71
Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017 72
Products under Development by Universities/Institutes, H2 2017 (Contd..3), H2 2017 73
Number of Products by Stage and Target, H2 2017 75
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 76
Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017 77
Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017 78
Number of Products by Stage and Target, H2 2017 (Contd..4), H2 2017 79
Number of Products by Stage and Target, H2 2017 (Contd..5), H2 2017 80
Number of Products by Stage and Target, H2 2017 (Contd..6), H2 2017 81
Number of Products by Stage and Target, H2 2017 (Contd..7), H2 2017 82
Number of Products by Stage and Target, H2 2017 (Contd..8), H2 2017 83
Number of Products by Stage and Mechanism of Action, H2 2017 85
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 86
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017 87
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017 88
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..4), H2 2017 89
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..5), H2 2017 90
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..6), H2 2017 91
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..7), H2 2017 92
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..8), H2 2017 93
Number of Products by Stage and Route of Administration, H2 2017 95
Number of Products by Stage and Molecule Type, H2 2017 97
Colon Cancer - Pipeline by 3-V Biosciences Inc, H2 2017 98
Colon Cancer - Pipeline by 4P-Pharma SAS, H2 2017 98
Colon Cancer - Pipeline by Actinium Pharmaceuticals Inc, H2 2017 99
Colon Cancer - Pipeline by Adamed Sp z oo, H2 2017 99
Colon Cancer - Pipeline by Adgero Biopharmaceuticals Holdings Inc, H2 2017 99
Colon Cancer - Pipeline by Aduro BioTech Inc, H2 2017 100
Colon Cancer - Pipeline by Advanced Cancer Therapeutics LLC, H2 2017 100
Colon Cancer - Pipeline by Advenchen Laboratories LLC, H2 2017 101
Colon Cancer - Pipeline by Aeglea BioTherapeutics Inc, H2 2017 101
Colon Cancer - Pipeline by Affimed GmbH, H2 2017 101
Colon Cancer - Pipeline by AGV Discovery SAS, H2 2017 102
Colon Cancer - Pipeline by AIMM Therapeutics BV, H2 2017 102
Colon Cancer - Pipeline by Ambrx Inc, H2 2017 103
Colon Cancer - Pipeline by Amgen Inc, H2 2017 103
Colon Cancer - Pipeline by Anavex Life Sciences Corp, H2 2017 104
Colon Cancer - Pipeline by AndroScience Corp, H2 2017 104
Colon Cancer - Pipeline by ANP Technologies Inc, H2 2017 104
Colon Cancer - Pipeline by Aphios Corp, H2 2017 105
Colon Cancer - Pipeline by Aposense Ltd, H2 2017 105
Colon Cancer - Pipeline by Aptose Biosciences Inc, H2 2017 106
Colon Cancer - Pipeline by Asana BioSciences LLC, H2 2017 106
Colon Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H2 2017 106
Colon Cancer - Pipeline by Batu Biologics Inc, H2 2017 107
Colon Cancer - Pipeline by Bayer AG, H2 2017 107
Colon Cancer - Pipeline by BCN Biosciences LLC, H2 2017 108
Colon Cancer - Pipeline by BeyondSpring Pharmaceuticals Inc, H2 2017 108
Colon Cancer - Pipeline by Bicycle Therapeutics Ltd, H2 2017 108
Colon Cancer - Pipeline by BioCancell Ltd, H2 2017 109
Colon Cancer - Pipeline by Biogazelle NV, H2 2017 109
Colon Cancer - Pipeline by Blirt SA, H2 2017 110
Colon Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2017 110
Colon Cancer - Pipeline by Can-Fite BioPharma Ltd, H2 2017 110
Colon Cancer - Pipeline by CBT Pharmaceuticals Inc, H2 2017 111
Colon Cancer - Pipeline by Celgene Corp, H2 2017 111
Colon Cancer - Pipeline by Celprogen Inc, H2 2017 112
Colon Cancer - Pipeline by Critical Outcome Technologies Inc, H2 2017 112
Colon Cancer - Pipeline by CrystalGenomics Inc, H2 2017 113
Colon Cancer - Pipeline by CytomX Therapeutics Inc, H2 2017 113
Colon Cancer - Pipeline by Cytune Pharma SAS, H2 2017 114
Colon Cancer - Pipeline by CZ BioMed Corp, H2 2017 114
Colon Cancer - Pipeline by Debiopharm International SA, H2 2017 114
Colon Cancer - Pipeline by DEKK-TEC Inc, H2 2017 115
Colon Cancer - Pipeline by Eli Lilly and Co, H2 2017 115
Colon Cancer - Pipeline by EntreChem SL, H2 2017 116
Colon Cancer - Pipeline by EnzymeBioSystems, H2 2017 116
Colon Cancer - Pipeline by F-star Biotechnology Ltd, H2 2017 116
Colon Cancer - Pipeline by Felicitex Therapeutics Inc, H2 2017 117
Colon Cancer - Pipeline by G1 Therapeutics Inc, H2 2017 117
Colon Cancer - Pipeline by GlaxoSmithKline Plc, H2 2017 118
Colon Cancer - Pipeline by GlycaNova Norway AS, H2 2017 118
Colon Cancer - Pipeline by GlycoMimetics Inc, H2 2017 118
Colon Cancer - Pipeline by Grunenthal GmbH, H2 2017 119
Colon Cancer - Pipeline by Halozyme Therapeutics Inc, H2 2017 119
Colon Cancer - Pipeline by Hamlet Pharma AB, H2 2017 120
Colon Cancer - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017 120
Colon Cancer - Pipeline by Histogen Inc, H2 2017 120
Colon Cancer - Pipeline by HitGen LTD, H2 2017 121
Colon Cancer - Pipeline by Horizon Pharma Plc, H2 2017 121
Colon Cancer - Pipeline by Hummingbird Bioscience Pte Ltd, H2 2017 122
Colon Cancer - Pipeline by Idera Pharmaceuticals Inc, H2 2017 122
Colon Cancer - Pipeline by Immix BioPharma Inc, H2 2017 123
Colon Cancer - Pipeline by Immune Pharmaceuticals Inc, H2 2017 123
Colon Cancer - Pipeline by Immunomedics Inc, H2 2017 124
Colon Cancer - Pipeline by Immunotope Inc, H2 2017 124
Colon Cancer - Pipeline by IMPACT Therapeutics Inc, H2 2017 124
Colon Cancer - Pipeline by Infinity Pharmaceuticals Inc, H2 2017 125
Colon Cancer - Pipeline by Innopharmax Inc, H2 2017 125
Colon Cancer - Pipeline by Intezyne Technologies Inc, H2 2017 126
Colon Cancer - Pipeline by Ironwood Pharmaceuticals Inc, H2 2017 126
Colon Cancer - Pipeline by Jasco Pharmaceuticals LLC, H2 2017 127
Colon Cancer - Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H2 2017 127
Colon Cancer - Pipeline by JW Pharmaceutical Corp, H2 2017 128
Colon Cancer - Pipeline by Karyopharm Therapeutics Inc, H2 2017 128
Colon Cancer - Pipeline by Kineta Inc, H2 2017 128
Colon Cancer - Pipeline by Kringle Pharma Inc, H2 2017 129
Colon Cancer - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017 129
Colon Cancer - Pipeline by Lipocure Ltd, H2 2017 130
Colon Cancer - Pipeline by Lixte Biotechnology Holdings Inc, H2 2017 130
Colon Cancer - Pipeline by Lupin Ltd, H2 2017 131
Colon Cancer - Pipeline by Lymphocyte Activation Technologies SA, H2 2017 131
Colon Cancer - Pipeline by MabVax Therapeutics Holdings Inc, H2 2017 132
Colon Cancer - Pipeline by MacroGenics Inc, H2 2017 132
Colon Cancer - Pipeline by Madrigal Pharmaceuticals Inc., H2 2017 133
Colon Cancer - Pipeline by MaxiVAX SA, H2 2017 133
Colon Cancer - Pipeline by Medicenna Therapeutics Corp, H2 2017 133
Colon Cancer - Pipeline by Merus NV, H2 2017 134
Colon Cancer - Pipeline by Microlin Bio Inc, H2 2017 134
Colon Cancer - Pipeline by Molecular Targeting Technologies Inc, H2 2017 135
Colon Cancer - Pipeline by MolMed SpA, H2 2017 135
Colon Cancer - Pipeline by Mologen AG, H2 2017 136
Colon Cancer - Pipeline by Monopar Therapeutics LLC, H2 2017 136
Colon Cancer - Pipeline by Multimmune GmbH, H2 2017 136
Colon Cancer - Pipeline by Nektar Therapeutics, H2 2017 137
Colon Cancer - Pipeline by Northwest Biotherapeutics Inc, H2 2017 137
Colon Cancer - Pipeline by Novartis AG, H2 2017 138
Colon Cancer - Pipeline by OncoResponse Inc, H2 2017 138
Colon Cancer - Pipeline by Oncovir Inc, H2 2017 139
Colon Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017 139
Colon Cancer - Pipeline by Orega Biotech SAS, H2 2017 139
Colon Cancer - Pipeline by OSE Immunotherapeutics, H2 2017 140
Colon Cancer - Pipeline by Panacea Pharmaceuticals Inc, H2 2017 140
Colon Cancer - Pipeline by Patrys Ltd, H2 2017 141
Colon Cancer - Pipeline by PharmaCyte Biotech Inc, H2 2017 141
Colon Cancer - Pipeline by Philogen SpA, H2 2017 141
Colon Cancer - Pipeline by Plexxikon Inc, H2 2017 142
Colon Cancer - Pipeline by Prosetta Biosciences Inc, H2 2017 142
Colon Cancer - Pipeline by Provecs Medical GmbH (Inactive), H2 2017 143
Colon Cancer - Pipeline by Provectus Biopharmaceuticals Inc, H2 2017 143
Colon Cancer - Pipeline by Qu Biologics Inc, H2 2017 143
Colon Cancer - Pipeline by Redx Pharma Plc, H2 2017 144
Colon Cancer - Pipeline by Rexahn Pharmaceuticals Inc, H2 2017 144
Colon Cancer - Pipeline by Rgenix Inc, H2 2017 145
Colon Cancer - Pipeline by Sareum Holdings Plc, H2 2017 145
Colon Cancer - Pipeline by Sierra Oncology Inc, H2 2017 146
Colon Cancer - Pipeline by Sigma-Tau SpA, H2 2017 146
Colon Cancer - Pipeline by Sirnaomics Inc, H2 2017 146
Colon Cancer - Pipeline by Somantix BV, H2 2017 147
Colon Cancer - Pipeline by Sorrento Therapeutics Inc, H2 2017 147
Colon Cancer - Pipeline by Spring Bank Pharmaceuticals Inc, H2 2017 148
Colon Cancer - Pipeline by Starpharma Holdings Ltd, H2 2017 148
Colon Cancer - Pipeline by Synergys Biotherapeutics Inc, H2 2017 148
Colon Cancer - Pipeline by Systimmune Inc, H2 2017 149
Colon Cancer - Pipeline by Taiwan Liposome Company Ltd, H2 2017 149
Colon Cancer - Pipeline by Takis Srl, H2 2017 150
Colon Cancer - Pipeline by Theravectys SA, H2 2017 150
Colon Cancer - Pipeline by Tiziana Life Sciences Plc, H2 2017 151
Colon Cancer - Pipeline by Transgene Biotek Ltd, H2 2017 151
Colon Cancer - Pipeline by TVAX Biomedical Inc, H2 2017 151
Colon Cancer - Pipeline by Tyg Oncology Ltd, H2 2017 152
Colon Cancer - Pipeline by Vaccibody AS, H2 2017 152
Colon Cancer - Pipeline by Vaccinogen Inc, H2 2017 152
Colon Cancer - Pipeline by Vault Pharma Inc, H2 2017 153
Colon Cancer - Pipeline by Vaxenta Biotechnologies, H2 2017 153
Colon Cancer - Pipeline by Vernalis Plc, H2 2017 154
Colon Cancer - Pipeline by VG Life Sciences Inc, H2 2017 154
Colon Cancer - Pipeline by Vivolux AB, H2 2017 154
Colon Cancer - Pipeline by Yakult Honsha Co Ltd, H2 2017 155
Colon Cancer - Pipeline by Zenith Epigenetics Ltd, H2 2017 155
Colon Cancer - Pipeline by ZIOPHARM Oncology Inc, H2 2017 156
Colon Cancer - Dormant Projects, H2 2017 749
Colon Cancer - Dormant Projects, H2 2017 (Contd..1), H2 2017 750
Colon Cancer - Dormant Projects, H2 2017 (Contd..2), H2 2017 751
Colon Cancer - Dormant Projects, H2 2017 (Contd..3), H2 2017 752
Colon Cancer - Dormant Projects, H2 2017 (Contd..4), H2 2017 753
Colon Cancer - Dormant Projects, H2 2017 (Contd..5), H2 2017 754
Colon Cancer - Dormant Projects, H2 2017 (Contd..6), H2 2017 755
Colon Cancer - Dormant Projects, H2 2017 (Contd..7), H2 2017 756
Colon Cancer - Dormant Projects, H2 2017 (Contd..8), H2 2017 757
Colon Cancer - Dormant Projects, H2 2017 (Contd..9), H2 2017 758
Colon Cancer - Dormant Projects, H2 2017 (Contd..10), H2 2017 759
Colon Cancer - Dormant Projects, H2 2017 (Contd..11), H2 2017 760
Colon Cancer - Discontinued Products, H2 2017 761

List of Figures
Number of Products under Development for Colon Cancer, H2 2017 40
Number of Products under Development by Companies, H2 2017 41
Number of Products under Development by Universities/Institutes, H2 2017 53
Number of Products by Top 10 Targets, H2 2017 74
Number of Products by Stage and Top 10 Targets, H2 2017 74
Number of Products by Top 10 Mechanism of Actions, H2 2017 84
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 84
Number of Products by Routes of Administration, H2 2017 94
Number of Products by Stage and Routes of Administration, H2 2017 94
Number of Products by Top 10 Molecule Types, H2 2017 96
Number of Products by Stage and Top 10 Molecule Types, H2 2017 96

【レポートのキーワード】

結腸がん

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 結腸がん:治療薬開発パイプライン分析(Colon Cancer - Pipeline Review, H2 2017)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆